The Edinburgh Lung Fibrosis Molecular Endotyping (ELFMEN) Study
Launched by UNIVERSITY OF EDINBURGH · Jul 10, 2019
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
BACKGROUND
Idiopathic pulmonary fibrosis (IPF) is a progressive form of lung scarring for which there is no proven treatment. Steroids and other potentially toxic drugs are often used but their efficacy is uncertain. The management of patients with IPF is particularly complex because firstly there are a number of closely related fibrosing lung conditions that 'look' like IPF but in which the prognosis is generally better and which more often respond to steroids and secondly even within the group of patients with IPF, there is a variability in the rate of progression so that it is hard to p...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients with interstitial lung disease attending the Edinburgh Lung Fibrosis service
- Exclusion Criteria:
- • candidates not a suitable for enrolment or unlikely to comply with the requirements of this study, in the opinion of the investigator, will be excluded.
About University Of Edinburgh
The University of Edinburgh, a prestigious institution renowned for its commitment to research excellence and innovation, serves as a leading clinical trial sponsor dedicated to advancing healthcare through rigorous scientific inquiry. With a strong emphasis on multidisciplinary collaboration, the university facilitates cutting-edge clinical studies that aim to explore novel therapies and improve patient outcomes. Leveraging its extensive network of researchers, healthcare professionals, and state-of-the-art facilities, the University of Edinburgh is at the forefront of translating scientific discoveries into practical applications, thereby contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials